What is BeOne Medicines AG?
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 47.58B, and a P/E ratio of 53.4x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 2673 shares $206k | 0 |
| 9-12months | 6105,283 shares $32.5M | 0 |